About c4 therapeutics inc - CCCC
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
CCCC At a Glance
C4 Therapeutics, Inc.
490 Arsenal Way
Watertown, Massachusetts 02472
| Phone | 1-617-231-0700 | Revenue | 35.95M | |
| Industry | Biotechnology | Net Income | -104,994,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1.02% | |
| Fiscal Year-end | 12 / 2026 | Employees | 104 | |
| View SEC Filings |
CCCC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.404 |
| Price to Book Ratio | 0.721 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.313 |
| Enterprise Value to Sales | -0.841 |
| Total Debt to Enterprise Value | -1.984 |
CCCC Efficiency
| Revenue/Employee | 345,644.231 |
| Income Per Employee | -1,009,557.692 |
| Receivables Turnover | 14.972 |
| Total Asset Turnover | 0.10 |
CCCC Liquidity
| Current Ratio | 7.814 |
| Quick Ratio | 7.814 |
| Cash Ratio | 7.524 |
CCCC Profitability
| Gross Margin | 77.815 |
| Operating Margin | -290.675 |
| Pretax Margin | -291.743 |
| Net Margin | -292.08 |
| Return on Assets | -29.103 |
| Return on Equity | -44.435 |
| Return on Total Capital | -33.166 |
| Return on Invested Capital | -35.824 |
CCCC Capital Structure
| Total Debt to Total Equity | 23.377 |
| Total Debt to Total Capital | 18.948 |
| Total Debt to Total Assets | 16.127 |
| Long-Term Debt to Equity | 20.895 |
| Long-Term Debt to Total Capital | 16.936 |